01 What is MOTS-c?
In plain English.
MOTS-c is a tiny peptide, only 16 amino acids long, that the body makes inside its own mitochondria, the cellular structures that produce energy. Unusually, the instructions for building it are stored not in the main cell nucleus but inside the mitochondrial DNA itself, hidden within the gene that codes for a piece of ribosomal machinery (12S rRNA). It was identified in 2015 by Lee and colleagues at USC and was one of the first peptides shown to be encoded this way.
In wellness clinics and biohacker circles it's now sold as an injectable peptide and pitched as an anti-ageing or metabolic-health booster, sometimes literally as "exercise in a vial." That framing is borrowed from mouse experiments, not human data.
02 How it works
The simple version, then the science.
Inside muscle cells, MOTS-c appears to activate AMPK, an enzyme the body uses as a low-fuel alarm. Switching AMPK on is roughly what physical exercise does: it tells cells to burn more glucose and fat for energy and to behave more like trained, well-conditioned tissue. In mice this seems to improve how the body handles sugar and how long the animals can run.
Go deeper · the proposed mechanism
The original Lee et al. 2015 work showed MOTS-c targets skeletal muscle, activates AMPK and the folate-methionine cycle, and improves glucose tolerance and insulin sensitivity in mice fed a high-fat diet. A 2021 Nature Communications paper from the same group (Reynolds et al.) reported that MOTS-c moves into the nucleus under metabolic stress and regulates nuclear gene expression, and that injecting MOTS-c into older mice improved running capacity. Plasma MOTS-c levels rise with acute exercise in young humans and are lower in people with obesity or insulin resistance, but these are observational correlations, not evidence that giving exogenous MOTS-c reproduces those effects.
03 What it's used for
Each use graded by how strong the evidence actually is.
- PreclinicalInsulin sensitivity & glucose homeostasisReproducible improvements in mouse models of obesity and high-fat-diet-induced insulin resistance. No controlled human trials in metabolic disease.
- PreclinicalExercise capacity & age-related physical declineOlder mice given MOTS-c ran further and longer in the 2021 Reynolds paper. The "exercise mimetic" claim rests almost entirely on this rodent work.
- PreclinicalMuscle mass & atrophy signallingRodent data suggest MOTS-c lowers myostatin and atrophy-related signalling. Not replicated in humans.
- AnecdotalAnti-ageing / longevity protocolsHeavily promoted by wellness clinics. No human longevity outcomes data exists for MOTS-c.
04 What the evidence says
MOTS-c is one of the most-hyped peptides in the longevity and biohacker scene, and it is also one of the most preclinical. The science is genuinely interesting: a peptide your own mitochondria encode, that responds to exercise and metabolic stress, and that produces large effects in rodent models of diabetes and ageing. The problem is that essentially all of those effects are in mice. The human side is mostly observational, plasma MOTS-c correlates with exercise status, age and metabolic health, which is suggestive but does not show that injecting extra MOTS-c does anything useful in people. CohBar Inc., the company most associated with developing mitochondrial-derived peptide drugs, wound down its operations in 2023, which is a meaningful negative signal about how readily this biology has translated to a viable clinical product. Honest read: a compelling preclinical signal, real mechanistic novelty, and an enormous gap between that and any evidence-based human use.
05 Dosing & administration
Reported in the literature, information not advice.
There is no approved human protocol. Online research-chemical communities describe milligram-range subcutaneous injections, often several times per week, but these regimens are not based on controlled human pharmacokinetic or efficacy studies. No safe or effective dose has been established in humans. A qualified clinician should be consulted before considering any peptide.
06 Side effects & safety
Long-term safety in humans is unknown, there are no large human clinical trials of MOTS-c. Short-term human safety data is essentially absent. Because MOTS-c affects mitochondrial signalling, AMPK and glucose handling, plausible concerns include hypoglycaemia (especially in anyone on insulin or sulfonylureas), interactions with metformin and other AMPK-active drugs, and unknown effects in cancer (AMPK signalling cuts both ways in tumour biology). Products sold as MOTS-c are unregulated research chemicals, purity, identity and dose-by-dose consistency are not guaranteed. People who are pregnant, breastfeeding, immunocompromised, diabetic, or taking other medicines should be especially cautious.
07 Where to buy (research use only)
Vetted on quality and transparency, not an endorsement to use.
08 Legal & regulatory status
- UKNot licensed as a medicine. Sold only as a "research chemical", not for human use.
- USNot FDA-approved. Not on the FDA's list of bulk substances permitted for compounding.
- EU / AUS / CANNo approved human medicine containing MOTS-c. Sale for human use is unlawful in most jurisdictions; "research use only" framing is standard.
- Sport (WADA)MOTS-c is not named explicitly on the current WADA Prohibited List, but as an unapproved investigational substance with claimed performance effects it can fall under S0 ("Non-Approved Substances"), which prohibits any pharmacological substance not addressed by other sections and not currently approved by any health authority. Treat as banned in tested sport.
09 Clinical studies & research
Primary sources. Read the science yourself.